Ligand Pharmaceuticals LGND Gain (loss) on mark-to-market of Escrowed Shares
Gain (loss) on mark-to-market of Escrowed Shares at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrealizedGainLossOnDerivatives.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's gain (loss) on mark-to-market of escrowed shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's gain (loss) on mark-to-market of escrowed shares?
- Ligand Pharmaceuticals (LGND) reported gain (loss) on mark-to-market of escrowed shares of -$837K in Q1 2026.
- How has Ligand Pharmaceuticals's gain (loss) on mark-to-market of escrowed shares changed year-over-year?
- Ligand Pharmaceuticals's gain (loss) on mark-to-market of escrowed shares decreased by 381.0% year-over-year, from -$174K to -$837K.
- What does gain (loss) on mark-to-market of escrowed shares mean?
- This represents the non-cash impact on net income from changes in the fair value of derivative financial instruments held by the company. It reflects market-driven fluctuations in hedging instruments or speculative positions that do not involve immediate cash settlement. Investors track this to understand how market volatility affects the company's reported earnings without impacting current liquidity.